Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines

Kelsey L. Pomykala, Johannes Czernin, Tristan R. Grogan, Wesley R. Armstrong, John Williams and Jeremie Calais
Journal of Nuclear Medicine March 2020, 61 (3) 405-411; DOI: https://doi.org/10.2967/jnumed.119.230318
Kelsey L. Pomykala
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
2Department of Radiology, David Geffen School of Medicine, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Czernin
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
3Institute of Urologic Oncology, UCLA, Los Angeles, California
4Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tristan R. Grogan
5Department of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wesley R. Armstrong
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Williams
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremie Calais
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
3Institute of Urologic Oncology, UCLA, Los Angeles, California
4Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 61 no. 3 405-411
DOI 
https://doi.org/10.2967/jnumed.119.230318
PubMed 
31541035

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication April 26, 2019
  • Accepted for publication August 7, 2019
  • Published online March 2, 2020.

Article Versions

  • previous version (September 20, 2019 - 13:44).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Kelsey L. Pomykala1,2,
  2. Johannes Czernin1,3,4,
  3. Tristan R. Grogan5,
  4. Wesley R. Armstrong1,
  5. John Williams1 and
  6. Jeremie Calais1,3,4
  1. 1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
  2. 2Department of Radiology, David Geffen School of Medicine, UCLA, Los Angeles, California
  3. 3Institute of Urologic Oncology, UCLA, Los Angeles, California
  4. 4Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California; and
  5. 5Department of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, California
  1. For correspondence or reprints contact: Jeremie Calais, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, 200 Medical Plaza, Suite B114-61, Los Angeles, CA 90095. E-mail: jcalais{at}mednet.ucla.edu
View Full Text

Statistics from Altmetric.com

Cited By...

  • 29 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Salvage therapy for prostate cancer after radical prostatectomy
    Nicholas G. Zaorsky, Jeremie Calais, Stefano Fanti, Derya Tilki, Tanya Dorff, Daniel E. Spratt, Amar U. Kishan
    Nature Reviews Urology 2021 18 11
  • Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer
    Ismaheel O. Lawal, Alfred Morgenstern, Mariza Vorster, Otto Knoesen, Johncy Mahapane, Khanyisile N. Hlongwa, Letjie C. Maserumule, Honest Ndlovu, Janet D. Reed, Gbenga O. Popoola, Kgomotso M. G. Mokoala, Amanda Mdlophane, Frank Bruchertseifer, Mike M. Sathekge
    European Journal of Nuclear Medicine and Molecular Imaging 2022 49 10
  • Factors Predicting Metastatic Disease in 68Ga-PSMA-11 PET–Positive Osseous Lesions in Prostate Cancer
    Le Wen Chiu, Courtney Lawhn-Heath, Spencer C. Behr, Roxanna Juarez, Paola M. Perez, Iryna Lobach, Matthew D. Bucknor, Thomas A. Hope, Robert R. Flavell
    Journal of Nuclear Medicine 2020 61 12
  • Head-To-Head Comparison of 68Ga-PSMA-11 PET/CT and 99mTc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A Meta-Analysis
    Gege Zhao, Bin Ji
    American Journal of Roentgenology 2022 219 3
  • The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer—A Practical Clinical Review
    Anna Rebecca Lisney, Conrad Leitsmann, Arne Strauß, Birgit Meller, Jan Alexander Bucerius, Carsten-Oliver Sahlmann
    Cancers 2022 14 15
  • Recent Advances in Nanomedicine for the Diagnosis and Treatment of Prostate Cancer Bone Metastasis
    Daniel E. Hagaman, Jossana A. Damasco, Joy Vanessa D. Perez, Raniv D. Rojo, Marites P. Melancon
    Molecules 2021 26 2
  • Primary staging in patients with intermediate- and high-risk prostate cancer: Multiparametric MRI and 68Ga-PSMA-PET/MRI – What is the value of quantitative data from multiparametric MRI alone or in conjunction with clinical information?
    Stephan M Skawran, Vanessa Sanchez, Soleen Ghafoor, Andreas M Hötker, Irene A Burger, Martin W Huellner, Daniel Eberli, Olivio F Donati
    European Journal of Radiology 2022 146
  • Recent advances in the targeted fluorescent probes for the detection of metastatic bone cancer
    Peng Wu, Daniel J. Siegwart, Hu Xiong
    Science China Chemistry 2021 64 8
  • Predictors of Bone Metastases at 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence
    Guido Rovera, Serena Grimaldi, Sara Dall’Armellina, Roberto Passera, Marco Oderda, Giuseppe Carlo Iorio, Alessia Guarneri, Paolo Gontero, Umberto Ricardi, Désirée Deandreis
    Diagnostics 2022 12 6
  • Prospective evaluation of 68Ga-PSMA-11 PET/CT in Chinese men with biochemical recurrence after radical prostatectomy for prostate cancer: relationships between location of recurrence, time after prostatectomy, and serum PSA level
    Liang Dong, Yinjie Zhu, Mei Xin, Baijun Dong, Jiahua Pan, Jianjun Liu, Sarah R. Amend, Wei Xue, Kenneth J. Pienta, Steven P. Rowe
    Medical Oncology 2020 37 10

Article usage

Article usage: September 2019 to October 2023

AbstractFullPdf
Sep 2019651089
Oct 2019334045
Nov 2019109020
Dec 2019111017
Jan 2020112024
Feb 202095017
Mar 2020129030105
Apr 20202772550
May 2020149329
Jun 20201081021
Jul 20206311
Aug 202082316
Sep 20201102357
Oct 2020664053
Nov 2020712853
Dec 2020535836
Jan 2021384819
Feb 2021366532
Mar 2021388061
Apr 2021336741
May 2021286041
Jun 2021277459
Jul 2021354855
Aug 2021204137
Sep 2021125531
Oct 2021156344
Nov 2021195933
Dec 2021179634
Jan 2022316033
Feb 2022435929
Mar 2022196947
Apr 2022174722
May 2022134827
Jun 2022173520
Jul 2022104323
Aug 2022125430
Sep 2022163931
Oct 2022185736
Nov 2022194730
Dec 2022145223
Jan 2023174719
Feb 2023134222
Mar 2023365738
Apr 2023243522
May 2023162423
Jun 2023105723
Jul 2023102624
Aug 2023143027
Sep 2023113721
Oct 2023144422
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (3)
Journal of Nuclear Medicine
Vol. 61, Issue 3
March 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines
Kelsey L. Pomykala, Johannes Czernin, Tristan R. Grogan, Wesley R. Armstrong, John Williams, Jeremie Calais
Journal of Nuclear Medicine Mar 2020, 61 (3) 405-411; DOI: 10.2967/jnumed.119.230318

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines
Kelsey L. Pomykala, Johannes Czernin, Tristan R. Grogan, Wesley R. Armstrong, John Williams, Jeremie Calais
Journal of Nuclear Medicine Mar 2020, 61 (3) 405-411; DOI: 10.2967/jnumed.119.230318
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Factors Predicting Metastatic Disease in 68Ga-PSMA-11 PET-Positive Osseous Lesions in Prostate Cancer
  • Google Scholar

More in this TOC Section

Theranostics

  • Comparison of 18F-DCFPyL and 68Ga-PSMA-11 PET-CT for eligibility screening for 177Lu-PSMA-617 therapy in metastatic castrate resistant prostate cancer: Should insurers consider these methods equivalent?
  • Evaluation of residual on syringe pump delivery system for PLUVICTO™ (Lu-177 vipivotide tetraxetan)
  • The effect of Lu-177 Pluvicto therapy treatments on PSA levels
Show more Theranostics

Clinical

  • Comparison of 18F-DCFPyL and 68Ga-PSMA-11 PET-CT for eligibility screening for 177Lu-PSMA-617 therapy in metastatic castrate resistant prostate cancer: Should insurers consider these methods equivalent?
  • Evaluation of residual on syringe pump delivery system for PLUVICTO™ (Lu-177 vipivotide tetraxetan)
  • The effect of Lu-177 Pluvicto therapy treatments on PSA levels
Show more Clinical

Similar Articles

Keywords

  • PSMA
  • PET/CT
  • prostate cancer
  • bone metastasis
  • field of view
  • guidelines
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire